- Home
- ENS vs RYTM Comparison
ENS vs RYTM Comparison
Compare ENS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENS
- RYTM
- Stock Information
- Founded
- ENS 1991
- RYTM 2008
- Country
- ENS United States
- RYTM United States
- Employees
- ENS N/A
- RYTM N/A
- Industry
- ENS Industrial Machinery/Components
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- ENS Technology
- RYTM Health Care
- Exchange
- ENS Nasdaq
- RYTM Nasdaq
- Market Cap
- ENS 3.7B
- RYTM 3.2B
- IPO Year
- ENS N/A
- RYTM 2017
- Fundamental
- Price
- ENS $93.07
- RYTM $54.80
- Analyst Decision
- ENS Buy
- RYTM Strong Buy
- Analyst Count
- ENS 3
- RYTM 12
- Target Price
- ENS $117.50
- RYTM $68.58
- AVG Volume (30 Days)
- ENS 381.6K
- RYTM 532.5K
- Earning Date
- ENS 05-21-2025
- RYTM 05-06-2025
- Dividend Yield
- ENS 1.03%
- RYTM N/A
- EPS Growth
- ENS 21.88
- RYTM N/A
- EPS
- ENS 8.05
- RYTM N/A
- Revenue
- ENS $3,553,458,000.00
- RYTM $130,126,000.00
- Revenue This Year
- ENS $1.96
- RYTM $47.06
- Revenue Next Year
- ENS $4.63
- RYTM $68.10
- P/E Ratio
- ENS $11.77
- RYTM N/A
- Revenue Growth
- ENS N/A
- RYTM 68.06
- 52 Week Low
- ENS $88.50
- RYTM $35.17
- 52 Week High
- ENS $112.53
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- ENS 36.66
- RYTM 53.63
- Support Level
- ENS $94.66
- RYTM $52.54
- Resistance Level
- ENS $99.52
- RYTM $55.87
- Average True Range (ATR)
- ENS 2.20
- RYTM 2.15
- MACD
- ENS -0.41
- RYTM 0.47
- Stochastic Oscillator
- ENS 7.43
- RYTM 86.57
About ENS EnerSys
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers worldwide. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.